Our analyses exposed a pro-metastatic program in melanoma where aberrantly expressed NR2F2-Iso2 regulates the transactivating capacity of NR2F2-Iso1 over differentiation (e.g., PMEL) and metastasis (e.g., SNAI1) - regulating gene sets (Fig. 5c). This evidence concerns the gene NR2F2 and melanoma.